⌕
Biomarin Pharmaceutical · BMRN · Nasdaq
Tenet 43 · Weak
Compare
$58.51+0.90%At closeTenet 43 · Weak
$58.51+0.52 (+0.90%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Biomarin Pharmaceutical (BMRN) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice
Business engineSteady: revenue compounds ~14.9%/yr (FY21→FY25), net margin 10.8%, and free cash flow (~$725.0M) tracks net income. Earnings are cash, not paper. Worth your attention in FY25: Share count (+8.0%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲12.9%
3,221.3
FY21→FY25CAGR +14.9%/yr
Net income ($M)▼18.3%
348.9
one-off year: see footnoteCAGR +35.1%/yr
Free cash flow ($M)▲48.7%
725.0
FY21→FY25CAGR +36.5%/yr
Diluted EPS▼18.6%
1.80
FY22→FY25CAGR +33.9%/yr
What the receipts whisper · what a headline number hides
Share count
+8.0%

182.9mn → 197.4mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.

Capex
$103.0M

+20.6% YoY in FY25 · 3.2% of revenue.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)3221.3Revenue−717.4COGS2503.8Gross profit−921.9R&D−1153.0SG&A409.5Op income−60.6Tax & other348.9Net income

11¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.

Margin trend · direction beats level Gross Operating Net
806040200%sector median net margin ~3%FY21FY25

Over this window: gross 74.5% → 77.7%. Net margin 10.8% is more than double the sector median.

The receipt · income statement · FY21–FY25 USD millions except per-share & ratios · hover a line for its definition
USD millions except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
3,655.13,221.32,853.92,419.22,096.01,846.3▲12.9%+14.9%
Cost of revenue
878.9717.4580.2532.1503.0470.5▲23.6%+11.1%
Gross profit
2,776.22,503.82,273.71,887.21,593.01,375.8▲10.1%+16.1%
Research & development
1,046.4921.9747.2746.8649.6628.8▲23.4%+10.0%
Selling, general & admin
1,433.71,153.01,009.0892.4823.2759.4▲14.3%+11.0%
Total operating expenses
2,662.32,094.31,789.51,701.41,432.01,458.1▲17.0%+9.5%
Operating incomefeeds ROC rank
113.9409.5484.2185.8161.0−82.3▼15.4%+36.5% (22→25)
Other income, net
−70.273.057.52.8−11.47.0——
Pretax income
43.7482.5541.8188.6149.6−75.3▼10.9%+47.8% (22→25)
Income tax
62.8133.6114.920.98.0−11.3▲16.3%+155.4% (22→25)
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings
−19.1348.9426.9167.6141.6−64.1▼18.3%+35.1% (22→25)
Per share
Diluted EPSbuyback-sensitive
−0.081.802.210.870.75−0.35▼18.6%+33.9% (22→25)
Diluted shares (mn)
193.59197.39196.71191.59188.96182.85▲0.3%+1.9%
Margins
Gross margin69th pct in Healthcare
76.0%77.7%79.7%78.0%76.0%74.5%▼1.9pp+3.2pp
Operating margin
3.1%12.7%17.0%7.7%7.7%−4.5%▼4.3pp+17.2pp
Net margin38th pct in Healthcare
−0.5%10.8%15.0%6.9%6.8%−3.5%▼4.1pp+14.3pp
† TTM = trailing four quarters through 2026-09-30.FY22 effective tax rate was 5% vs a 15% norm for this window, likely a one-time item; see the filing.FY25 effective tax rate was 28% vs a 15% norm for this window, likely a one-time item; see the filing.
FY08 – FY20 · 13 more years
Unlock the full history →
5 more years of statements and CSV export are on Premium, and 13 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-02-26 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Biomarin Pharmaceutical's revenue last fiscal year?

Biomarin Pharmaceutical reported revenue of $3,221.3M in fiscal 2025, up 12.9% from fiscal 2024.

What was Biomarin Pharmaceutical's net income?

Biomarin Pharmaceutical reported net income of $348.9M in fiscal 2025, a net margin of 10.8%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.